- Completed
NCT01464034: Phase 1/2 - Carfilzomib, Pomalidomide With Dexamethasone in Patients With RRMM
Updated: Sep 27, 2022
NCT01464034: Phase 1/2: A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
KPd
A Safety and Efficacy Study of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
This is a dose finding pilot study to evaluate the safety and determine the maximum tolerated dose of the combination of carfilzomib and pomalidomide with dexamethasone (CPD) in patients with relapsed or refractory multiple myeloma followed by a phase II expansion at the MTD to evaluate efficacy.
Sponsor
Collaborators
ClinicalTrials.gov Identifier: NCT01464034
Official Title: A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma
First Posted : November 3, 2011
Click here for details on ClinicalTrials.gov
Pomalidomide: National Cancer Institute
Pomalidomide: MedlinePlus Drug Information
Carfilzomib : National Cancer Institute
Carfilzomib : MedlinePlus Drug Information
Dexamethasone : National Cancer Institute
Dexamethasone : MedlinePlus Drug Information
Drug: Carfilzomib
Drug: Pomalidomide
Drug: Dexamethasone
Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
Blood. 2015 Nov
Locations
United States, Georgia
United States, Indiana
United States, New Jersey
United States, New York
United States, North Carolina
United States, Pennsylvania
United States, Texas
United States, Washington